Robert W Schrier
Overview
Explore the profile of Robert W Schrier including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
212
Citations
7787
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dad T, Abebe K, Bae K, Comer D, Torres V, Czarnecki P, et al.
Kidney Int Rep
. 2018 Jun;
3(3):619-624.
PMID: 29854969
Introduction: The high burden of cardiovascular morbidity and mortality in autosomal dominant polycystic kidney disease (ADPKD) is related to development of hypertension and left ventricular hypertrophy. Blood pressure reduction has...
2.
Brosnahan G, Abebe K, Moore C, Rahbari-Oskoui F, Bae K, Grantham J, et al.
Am J Kidney Dis
. 2018 Jan;
71(5):666-676.
PMID: 29306517
Background: Previous clinical studies of autosomal dominant polycystic kidney disease (ADPKD) reported that loss of kidney function usually follows a steep and relentless course. A detailed examination of individual patterns...
3.
Braun W, Abebe K, Brosnahan G, Patterson C, Chapman A, Harris P, et al.
Am J Kidney Dis
. 2017 Dec;
71(2):294-296.
PMID: 29203126
No abstract available.
4.
Chonchol M, Gitomer B, Isakova T, Cai X, Salusky I, Pereira R, et al.
Clin J Am Soc Nephrol
. 2017 Jul;
12(9):1461-1469.
PMID: 28705885
Background And Objectives: Increases in fibroblast growth factor 23 precede kidney function decline in autosomal dominant polycystic kidney disease; however, the role of fibroblast growth factor 23 in autosomal dominant...
5.
Brosnahan G, Abebe K, Rahbari-Oskoui F, Patterson C, Bae K, Schrier R, et al.
Curr Hypertens Rev
. 2017 May;
13(2):109-120.
PMID: 28460625
Background: Autosomal dominant polycystic kidney disease (ADPKD) commonly results in end-stage renal disease (ESRD), yet a long-term treatment that is well tolerated is still lacking. In a small randomized trial...
6.
Torres V, Abebe K, Schrier R, Perrone R, Chapman A, Yu A, et al.
Kidney Int
. 2016 Dec;
91(2):493-500.
PMID: 27993381
The CRISP study of polycystic kidney disease (PKD) found that urinary sodium excretion associated with the rate of total kidney volume increase. Whether sodium restriction slows the progression of Autosomal...
7.
Schrier R
Pharmacol Res
. 2016 Oct;
114:166-168.
PMID: 27794499
The review focuses on the common kidney disorder of Autosomal Dominant Polycystic Kidney Disease (ADPKD). The potential pathogenetic role of the renin-angiotensin-aldosterone system (RAAS) in the renal cyst growth, the...
8.
Nowak K, Cadnapaphornchai M, Chonchol M, Schrier R, Gitomer B
Am J Nephrol
. 2016 Aug;
44(3):171-8.
PMID: 27548646
Background: Long-term clinical outcomes in children with very-early onset (VEO; diagnosis in utero or within the first 18 months of life) autosomal dominant polycystic kidney disease (ADPKD) are currently not...
9.
Irazabal M, Abebe K, Bae K, Perrone R, Chapman A, Schrier R, et al.
Nephrol Dial Transplant
. 2016 Aug;
32(11):1857-1865.
PMID: 27484667
Background: Patients with mild autosomal dominant polycystic kidney disease (ADPKD) are less likely to be informative in randomized clinical trials (RCTs). We previously developed an imaging classification of ADPKD (typical...
10.
Heyer C, Sundsbak J, Abebe K, Chapman A, Torres V, Grantham J, et al.
J Am Soc Nephrol
. 2016 Jan;
27(9):2872-84.
PMID: 26823553
Autosomal dominant polycystic kidney disease (ADPKD) often results in ESRD but with a highly variable course. Mutations to PKD1 or PKD2 cause ADPKD; both loci have high levels of allelic...